Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs iShares Core MSCI EAFE ETF (IEFA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs iShares Core MSCI EAFE ETF — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while iShares Core MSCI EAFE ETF trades at $97.97. The key difference: iShares Core MSCI EAFE ETF is trading nearer its 52-week high, Bio-Rad Laboratories, Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals.
| BIO | IEFA | |
|---|---|---|
Market Cap | $8.04B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $339.75 | $98.56 |
52-Week Low | $241.71 | $81.70 |
Enterprise Value | $7.85B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
IEFA trades at $96.15, down 1.1% on the day, with technical indicators showing a neutral to bearish short-term bias. The ETF provides exposure to developed international markets outside the US and Canada, offering diversification benefits amid S&P 500 concentration concerns. Recent news highlights IEFA's competitive 3.30% dividend yield and low 0.07% expense ratio compared to peers like VXUS and EEM.
The outlook remains balanced with potential upside from Fed rate cuts and international diversification benefits, offset by currency risks and developed market monetary policy tightening. IEFA's low-cost structure and dividend yield provide defensive characteristics, though performance depends heavily on international economic conditions and currency movements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →
